Recently Added Drugs
1. Ambelvist patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10137209 | BAYER | Gadolinium Chelate Compounds For Use In Magnetic Resonance Imaging |
May, 2036
(9 years from now) | |
| US10722601 | BAYER | Gadolinium Chelate Compounds For Use In Magnetic Resonance Imaging |
May, 2036
(9 years from now) | |
| US11491245 | BAYER | Gadolinium Chelate Compounds For Use In Magnetic Resonance Imaging |
May, 2036
(9 years from now) | |
| US12478696 | BAYER | Gadolinium Chelate Compounds For Use In Magnetic Resonance Imaging |
May, 2036
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12303573 | BAYER | Formulation Of Contrast Media And Process Of Preparation Thereof |
Nov, 2039
(13 years from now) | |
| US11944690 | BAYER | Formulation Of Contrast Media And Process Of Preparation Thereof |
May, 2040
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 12, 2031 |
Drugs and Companies using GADOQUATRANE ingredient
NCE-1 date: 12 June, 2030
Market Authorisation Date: 12 June, 2026
Treatment: Method of magnetic resonance imaging to detect and visualize lesions with abnormal vascularity in the central nervous system (brain, spine, and associated tissues) and the body (head and neck, thorax,...
Dosage: SOLUTION
More Information on Dosage
AMBELVIST family patents
2. Aristada patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12653822 | ALKERMES | Aripiprazole Formulations Having Increased Injection Speeds |
Mar, 2035
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 05, 2020 |
Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient
NCE-1 date: 06 October, 2019
Market Authorisation Date: 05 October, 2015
Treatment: Treatment of schizophrenia by rapid and continuous intramuscular injection
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
ARISTADA family patents
3. Auvelity patent
expiration
Can you believe AUVELITY received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12661408 | AXSOME | Pharmaceutical Compositions Comprising Bupropion And Cysteine |
Jan, 2043
(16 years from now) | |
| US12678506 | AXSOME | Pharmaceutical Compositions Comprising Bupropion And Cysteine |
Jan, 2043
(16 years from now) | |
| US12653795 | AXSOME | NA |
Nov, 2043
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 18, 2025 |
| New Indication(I-913) | Apr 30, 2029 |
Drugs and Companies using BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE ingredient
Market Authorisation Date: 30 April, 2026
Treatment: Dextromethorphan and bupropion in combination to treat major depressive disorder; The treatment of agitation associated with dementia due to alzheimer’s disease
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of AUVELITY before its drug patent expiration?
More Information on Dosage
AUVELITY family patents
4. Balversa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12678498 | JANSSEN | Fgfr/Pd-1 Combination Therapy For The Treatment Of Cancer |
Jun, 2036
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 12, 2024 |
| New Indication(I-930) | Jan 19, 2027 |
Drugs and Companies using ERDAFITINIB ingredient
NCE-1 date: 13 April, 2023
Market Authorisation Date: 12 April, 2019
Treatment: Treatment of adults with locally advanced or metastatic urothelial carcinoma with susceptible fgfr3 genetic alterations (including g370c) whose disease has progressed on or after prior pd-1 or pd-l1 i...
Dosage: TABLET
How can I launch a generic of BALVERSA before its drug patent expiration?
More Information on Dosage
BALVERSA family patents
5. Crexont patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12691074 | IMPAX | NA |
Oct, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 07, 2027 |
Drugs and Companies using CARBIDOPA; LEVODOPA ingredient
Market Authorisation Date: 07 August, 2024
Treatment: NA
Dosage: CAPSULE, EXTENDED RELEASE
How can I launch a generic of CREXONT before its drug patent expiration?
More Information on Dosage
CREXONT family patents
6. Descovy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12678408 | GILEAD | Pharmaceutical Formulations Comprising Tenofovir Alafenamide And Emtricitabine |
Jun, 2036
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 28, 2020 |
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
| New Indication(I-812) | Oct 03, 2022 |
| Orphan Drug Exclusivity(ODE-284) | Sep 28, 2024 |
| Orphan Drug Exclusivity(ODE-285) | Sep 28, 2024 |
| M(M-316) | Jun 20, 2028 |
| Orphan Drug Exclusivity(ODE-457) | Jan 07, 2029 |
| Orphan Drug Exclusivity(ODE-554) | Jan 07, 2029 |
| Orphan Drug Exclusivity(ODE-556) | Jun 20, 2032 |
Drugs and Companies using EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient
NCE-1 date: 06 November, 2019
Market Authorisation Date: 07 January, 2022
Treatment: NA
Dosage: TABLET
How can I launch a generic of DESCOVY before its drug patent expiration?
More Information on Dosage
DESCOVY family patents
7. Epidiolex patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12661365 | JAZZ | Use Of Cannabidiol In The Treatment Of Epilepsy |
Sep, 2042
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jul 31, 2023 |
| New Chemical Entity Exclusivity(NCE) | Sep 28, 2023 |
| Orphan Drug Exclusivity(ODE-216) | Sep 28, 2025 |
| M(M-270) | Oct 20, 2026 |
| Orphan Drug Exclusivity(ODE-326) | Jul 31, 2027 |
| Orphan Drug Exclusivity(ODE-332) | Jul 31, 2027 |
Drugs and Companies using CANNABIDIOL ingredient
NCE-1 date: 28 September, 2022
Market Authorisation Date: 28 September, 2018
Treatment: Use for the treatment of dravet syndrome in a patient taking caffeine concurrently
Dosage: SOLUTION
How can I launch a generic of EPIDIOLEX before its drug patent expiration?
More Information on Dosage
EPIDIOLEX family patents
8. Gavreto patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12655128 | RIGEL | Inhibitors Of Ret |
Nov, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 04, 2025 |
| Orphan Drug Exclusivity(ODE-318) | Sep 04, 2027 |
| Orphan Drug Exclusivity(ODE-340) | Dec 01, 2027 |
| Orphan Drug Exclusivity(ODE-341) | Dec 01, 2027 |
Drugs and Companies using PRALSETINIB ingredient
NCE-1 date: 04 September, 2024
Market Authorisation Date: 04 September, 2020
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
GAVRETO family patents
9. Hydromorphone Hydrochloride patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12653820 | HIKMA | Hydromorphone Formulations For Multi-Dose Products |
Jan, 2043
(16 years from now) | |
Drugs and Companies using HYDROMORPHONE HYDROCHLORIDE ingredient
Market Authorisation Date: 14 December, 2023
Treatment: Use of hydromorphone hydrochloride for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
Dosage: SOLUTION
More Information on Dosage
HYDROMORPHONE HYDROCHLORIDE family patents
10. Hyrnuo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12679836 | BAYER | 4H-Pyrrolo[3,2-C]Pyridin-4-One Compounds |
Nov, 2043
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 19, 2030 |
Drugs and Companies using SEVABERTINIB ingredient
NCE-1 date: 19 November, 2029
Market Authorisation Date: 19 November, 2025
Treatment: Treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (nsclc) whose tumors have her2 (erbb2) tyrosine kinase domain (tkd) activating mutations and who...
Dosage: TABLET
More Information on Dosage
HYRNUO family patents
11. Iqirvo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12673035 | IPSEN | Solid Dosage Forms Of Elafibranor |
Mar, 2044
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 10, 2029 |
| Orphan Drug Exclusivity(ODE-486) | Jun 10, 2031 |
Drugs and Companies using ELAFIBRANOR ingredient
NCE-1 date: 10 June, 2028
Market Authorisation Date: 10 June, 2024
Treatment: Treatment of primary biliary cholangitis (pbc)
Dosage: TABLET
More Information on Dosage
IQIRVO family patents
12. Jentadueto patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12678442 | BOEHRINGER INGELHEIM | Dpp-Iv Inhibitor Combined With A Further Antidiabetic Agent, Tablets Comprising Such Formulations, Their Use And Process For Their Preparation |
Apr, 2029
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jan 30, 2015 |
| New Chemical Entity Exclusivity(NCE) | May 02, 2016 |
| M(M-146) | Jul 30, 2017 |
| M(M-258) | Jul 03, 2022 |
| M(M-252) | Mar 30, 2023 |
| M(M-295) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 03 May, 2015
Market Authorisation Date: 30 January, 2012
Treatment: NA
Dosage: TABLET
How can I launch a generic of JENTADUETO before its drug patent expiration?
More Information on Dosage
JENTADUETO family patents
13. Jentadueto Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12678442 | BOEHRINGER INGELHEIM | Dpp-Iv Inhibitor Combined With A Further Antidiabetic Agent, Tablets Comprising Such Formulations, Their Use And Process For Their Preparation |
Apr, 2029
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-258) | Jul 03, 2022 |
| M(M-252) | Mar 30, 2023 |
| M(M-295) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 27 May, 2016
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of JENTADUETO XR before its drug patent expiration?
More Information on Dosage
JENTADUETO XR family patents
14. Jideytro patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11542278 | NUVALENT | NA |
May, 2041
(14 years from now) | |
| US12043626 | NUVALENT | Solid Forms, Pharmaceutical Compositions And Preparation Of Heteroaromatic Macrocyclic Ether Compounds |
Sep, 2042
(16 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12054498 | NUVALENT | Heteroaromatic Macrocyclic Ether Chemotherapeutic Agents |
May, 2041
(14 years from now) | |
| US12630560 | NUVALENT | Solid Forms, Pharmaceutical Compositions And Preparation Of Heteroaromatic Macrocyclic Ether Compounds |
Sep, 2042
(16 years from now) | |
Drugs and Companies using ZIDESAMTINIB ingredient
Market Authorisation Date: 22 July, 2026
Treatment: Treatment of adult patients with locally advanced or metastatic ros1-positive non-small cell lung cancer (nsclc) who have received at least one prior ros1 kinase inhibitor
Dosage: TABLET
More Information on Dosage
JIDEYTRO family patents
15. Klisyri patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12667576 | ALMIRALL | Methods Of Treating And/Or Preventing Actinic Keratosis |
Mar, 2038
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 14, 2025 |
| New Dosing Schedule(D-192) | Jun 07, 2027 |
Drugs and Companies using TIRBANIBULIN ingredient
NCE-1 date: 14 December, 2024
Market Authorisation Date: 14 December, 2020
Treatment: Topical field treatment of actinic keratosis on the face or scalp
Dosage: OINTMENT
How can I launch a generic of KLISYRI before its drug patent expiration?
More Information on Dosage
KLISYRI family patents
16. Krazati patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12653789 | BRISTOL | Adagrasib Solid Pharmaceutical Compositions |
Aug, 2043
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 12, 2027 |
| Orphan Drug Exclusivity(ODE-352) | Dec 12, 2029 |
Drugs and Companies using ADAGRASIB ingredient
NCE-1 date: 12 December, 2026
Market Authorisation Date: 12 December, 2022
Treatment: NA
Dosage: TABLET
More Information on Dosage
KRAZATI family patents
17. Lasix Onyu patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11246851 | SQ INNOVATION | Pharmaceutical Compositions Of Furosemide And Uses Thereof |
Jan, 2040
(13 years from now) | |
| US12318363 | SQ INNOVATION | Pharmaceutical Compositions Of Furosemide And Uses Thereof |
Jan, 2040
(13 years from now) | |
| US12403120 | SQ INNOVATION | Pharmaceutical Compositions Of Furosemide And Uses Thereof |
Jan, 2042
(15 years from now) | |
Drugs and Companies using FUROSEMIDE ingredient
Market Authorisation Date: 07 October, 2025
Treatment: Treatment of edema in adult patients with chronic heart failure
Dosage: SOLUTION
More Information on Dosage
LASIX ONYU family patents
18. Lipfendra patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11427616 | MERCK | Pcsk9 Antagonist Compounds |
Feb, 2040
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 15, 2031 |
Drugs and Companies using ENLICITIDE DECANOATE ingredient
NCE-1 date: 15 July, 2030
Market Authorisation Date: 15 July, 2026
Treatment: Reduction of ldl-c in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (hefh)
Dosage: TABLET
More Information on Dosage
LIPFENDRA family patents
19. Livtencity patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12661368 | TAKEDA | Maribavir Isomers, Compositions, Methods Of Making And Methods Of Using |
Oct, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 23, 2026 |
| Orphan Drug Exclusivity(ODE-388) | Nov 23, 2028 |
Drugs and Companies using MARIBAVIR ingredient
NCE-1 date: 23 November, 2025
Market Authorisation Date: 23 November, 2021
Treatment: Treatment with 400 mg maribavir twice daily in immediate release formulation for patients with post-transplant cytomegalovirus infection/disease refractory to (with/without genotypic resistance) ganci...
Dosage: TABLET
How can I launch a generic of LIVTENCITY before its drug patent expiration?
More Information on Dosage
LIVTENCITY family patents
20. Potassium Phosphates In 0.9% Sodium Chloride patent expiration
POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11925661 | AMNEAL | Ready-to-use potassium phosphates in sodium chloride solutions |
Oct, 2041
(15 years from now) | |
Drugs and Companies using POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC ingredient
Market Authorisation Date: 26 July, 2024
Treatment: Method to provide phosphorus replacement by administering without prior dilution an isotonic, sterile, and ready-to-use solution comprising about 15 mmol phosphorus and about 22 meq potassium from a f...
Dosage: SOLUTION
More Information on Dosage
POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE family patents
21. Qlonilik patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12551466 | CMP DEV | NA |
Aug, 2045
(19 years from now) | |
Drugs and Companies using CLONIDINE HYDROCHLORIDE ingredient
Market Authorisation Date: 29 July, 2026
Treatment: Qlonilik (clonidine hydrochloride) oral solution is indicated for the treatment of hypertension, to lower blood pressure in adults
Dosage: SOLUTION
More Information on Dosage
QLONILIK family patents
22. Rezdiffra patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12661359 | MADRIGAL | Therapeutic Combinations Of Rosuvastatin And Resmetirom For The Treatment Of Liver Disorders Or Lipid Disorders |
Jan, 2042
(15 years from now) | |
| US12667575 | MADRIGAL | Methods For Treating A Fatty Liver Disease |
Feb, 2045
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 14, 2029 |
Drugs and Companies using RESMETIROM ingredient
NCE-1 date: 14 March, 2028
Market Authorisation Date: 14 March, 2024
Treatment: Treatment of adults with noncirrhotic nonalcoholic steatohepatitis (nash) in patients receiving rosuvastatin; Treatment of adults with noncirrhotic nonalcoholic steatohepatitis (nash) with moderate to...
Dosage: TABLET
More Information on Dosage
REZDIFFRA family patents
23. Romvimza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12686672 | DECIPHERA | NA |
Apr, 2045
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 14, 2030 |
Drugs and Companies using VIMSELTINIB ingredient
NCE-1 date: 14 February, 2029
Market Authorisation Date: 14 February, 2025
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
ROMVIMZA family patents
24. Ryaltris patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12653833 | GLENMARK | Nasal Spray Composition |
Nov, 2044
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 13, 2025 |
| New Patient Population(NPP) | Jul 07, 2029 |
Drugs and Companies using MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 13 January, 2022
Treatment: Treatment of seasonal allergic rhinitis by nasally administering a combination of olopatadine hydrochloride and mometasone furoate in a composition including glycerin
Dosage: SPRAY, METERED
More Information on Dosage
RYALTRIS family patents
25. Tadliq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12691120 | CMP DEV | NA |
Dec, 2038
(12 years from now) | |
| US12697338 | CMP DEV | NA |
Dec, 2038
(12 years from now) | |
Drugs and Companies using TADALAFIL ingredient
Market Authorisation Date: 17 June, 2022
Treatment: Tadliq is indicated for the treatment of pulmonary arterial hypertension (pah) (who group 1) to improve exercise ability
Dosage: SUSPENSION
How can I launch a generic of TADLIQ before its drug patent expiration?
More Information on Dosage
TADLIQ family patents
26. Trijardy Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12678442 | BOEHRINGER INGELHEIM | Dpp-Iv Inhibitor Combined With A Further Antidiabetic Agent, Tablets Comprising Such Formulations, Their Use And Process For Their Preparation |
Apr, 2029
(2 years from now) | |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 27 January, 2020
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of TRIJARDY XR before its drug patent expiration?
More Information on Dosage
TRIJARDY XR family patents
27. Tryngolza (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9127276 | IONIS | Conjugated antisense compounds and their use |
May, 2034
(7 years from now) | |
| US9163239 | IONIS | Compositions and methods for modulating apolipoprotein C-III expression |
May, 2034
(7 years from now) | |
| US9181549 | IONIS | Conjugated antisense compounds and their use |
May, 2034
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9157082 | IONIS | Modulation of apolipoprotein CIII (ApoCIII) expression |
Apr, 2032
(5 years from now) | |
| US12509684 | IONIS | Compositions And Methods For Modulating Apolipoprotein C-Iii Expression |
May, 2034
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-992) | Jun 24, 2029 |
| New Strength(NS) | Jun 24, 2029 |
| Orphan Drug Exclusivity(ODE-515) | Dec 19, 2031 |
Drugs and Companies using OLEZARSEN SODIUM ingredient
Market Authorisation Date: 24 June, 2026
Treatment: Use in reducing triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (shtg: tg greater than or equal to 500 mg/dl)
Dosage: SOLUTION
More Information on Dosage
TRYNGOLZA (AUTOINJECTOR) family patents
28. Utebzi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10889587 | GLAXOSMITHKLINE | Tebipenem Pivoxil Crystalline Forms, Compositions Including The Same, Methods Of Manufacture, And Methods Of Use |
Feb, 2038
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12226403 | GLAXOSMITHKLINE | Tebipenem Pivoxil Immediate And Modified Release Oral Dosage Forms |
Dec, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 17, 2031 |
| Generating Antibiotic Incentives Now(GAIN) | Jun 17, 2036 |
Drugs and Companies using TEBIPENEM PIVOXIL HYDROBROMIDE ingredient
NCE-1 date: 17 June, 2030
Market Authorisation Date: 17 June, 2026
Treatment: Treatment of complicated urinary tract infections caused by e. coli, k. pneumoniae, ecc, k. oxytoca, or e. faecalis in patients who have limited or no alternative oral treatment options with a dosage ...
Dosage: TABLET
More Information on Dosage
UTEBZI family patents
29. Vizz patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12653779 | LENZ | Compositions And Methods For The Treatment Of Presbyopia |
Jun, 2035
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2030 |
Drugs and Companies using ACECLIDINE HYDROCHLORIDE ingredient
NCE-1 date: 31 July, 2029
Market Authorisation Date: 31 July, 2025
Treatment: Treatment of presbyopia
Dosage: SOLUTION/DROPS
More Information on Dosage
VIZZ family patents
30. Vyscoxa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12678405 | CARWIN ASSOC | NA |
Sep, 2045
(19 years from now) | |
Drugs and Companies using CELECOXIB ingredient
Market Authorisation Date: 29 July, 2025
Treatment: NA
Dosage: SUSPENSION
More Information on Dosage
VYSCOXA family patents
31. Wegovy Flextouch patent expiration
WEGOVY FLEXTOUCH's oppositions filed in EPO
WEGOVY FLEXTOUCH IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8129343 | NOVO NORDISK | Acylated GLP-1 compounds |
Dec, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9764003 | NOVO NORDISK | Use of long-acting GLP-1 peptides |
Jun, 2033
(6 years from now) | |
| US12029779 | NOVO NORDISK | Semaglutide in medical therapy |
Oct, 2038
(12 years from now) | |
| US12551536 | NOVO NORDISK | Semaglutide In Medical Therapy |
Oct, 2038
(12 years from now) | |
| US11478533 | NOVO NORDISK | Semaglutide For Use In Medicine |
May, 2040
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-935) | Mar 08, 2027 |
| New Indication(I-973) | Aug 15, 2028 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 04 June, 2021
Treatment: Method for weight management according to a dose escalation schedule; Method for weight management; Method of weight reduction via subcutaneous administration; Treatment of adults with noncirrhotic no...
Dosage: SOLUTION
How can I launch a generic of WEGOVY FLEXTOUCH before its drug patent expiration?
More Information on Dosage
WEGOVY FLEXTOUCH family patents
32. Welireg patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10335388 | MERCK | Combination Therapy Of A Hif-2-Alpha Inhibitor And An Immunotherapeutic Agent And Uses Thereof |
Apr, 2036
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 13, 2026 |
| New Indication(I-931) | Dec 14, 2026 |
| New Indication(I-968) | May 14, 2028 |
| Orphan Drug Exclusivity(ODE-364) | Aug 13, 2028 |
| New Indication(I-994) | Jun 12, 2029 |
Drugs and Companies using BELZUTIFAN ingredient
NCE-1 date: 13 August, 2025
Market Authorisation Date: 13 August, 2021
Treatment: In combination with pembrolizumab or pembrolizumab/berahyaluronidase alfa, for adjuvant treatment of adults with ccrcc at intermediate-high or high risk of recurrence following (1) nephrectomy or (2) ...
Dosage: TABLET
How can I launch a generic of WELIREG before its drug patent expiration?
More Information on Dosage
WELIREG family patents
33. Xelstrym patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12678504 | NOVEN | Stable Transdermal Amphetamine Compositions And Methods Of Manufacture |
Mar, 2034
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 22, 2025 |
Drugs and Companies using DEXTROAMPHETAMINE ingredient
Market Authorisation Date: 22 March, 2022
Treatment: Method of transdermally administering dextroamphetamine
Dosage: SYSTEM
More Information on Dosage
XELSTRYM family patents
34. Zilxi patent expiration
Can you believe ZILXI received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12661407 | JOURNEY | Compositions, Gels And Foams With Rheology Modulators And Uses Thereof |
Oct, 2030
(4 years from now) | |
Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 May, 2020
Treatment: Treatment of inflammatory lesions of rosacea
Dosage: AEROSOL, FOAM
How can I launch a generic of ZILXI before its drug patent expiration?
More Information on Dosage
ZILXI family patents
35. Zonisade patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12685723 | AZURITY | NA |
Aug, 2038
(11 years from now) | |
Drugs and Companies using ZONISAMIDE ingredient
Market Authorisation Date: 15 July, 2022
Treatment: NA
Dosage: SUSPENSION
How can I launch a generic of ZONISADE before its drug patent expiration?
More Information on Dosage
ZONISADE family patents